

AMARIN - List of products

PRODUCT	DEVELOPMENT STAGE	REFERENCE PRODUCTS	STRENGTHS AND DOSAGES	THERAPEUTIC USE
FENTANYL TDS	Marketed product	Durogesic® (Janssen)	25, 50, 75, 100 mcg/h	Management of pain in opioid-tolerant patients
RIVASTIGMINE TDS *	Marketed product	Exelon® (Novartis)	4.6; 9.5 and 13.3 mg/24 h	Alzheimer disease. Dementia associated with Parkinson disease
DICLOFENAC SODIUM GEL 1%	Approved by FDA	Voltaren® (GSK)	1%	Osteoarthritis of joints amenable to topical treatment
ESTRADIOL GEL	Marketed product	Estrogel® (Ascend)	0.06%	Hormonal replacement therapy
DICLOFENAC DIETHYLAMINE GEL	Marketed product	Voltaren Emulgel® (GSK)	1.16%	Acute musculoskeletal disorders
DICLOFENAC SODIUM GEL 5%	Marketed product	Diclac® (Hexal)	5%	Osteoarthritis, soft-tissue rheumatism, traumatism
TESTOSTERONE GEL	Marketed product	Androgel® (Abbie)	1%; 1.62%	Replacement therapy for deficiency or absence of endogenous testosterone
DICLOFENAC DIETHYLAMINE TDS	Marketed product	Nupatch® (Zidus Cadila)	200mg	Osteoarthritis, Rheumatoid arthritis, and other musculoskeletal disorders.
SELEGILINE TDS *	Bioequivalence Stage Product Developed	Emsam® (Dey L.P./Somerset)	6; 9 and 12 mg/d	Major depressive disorders
BUPRENORPHINE TDS *	Bioequivalence Stage Product Developed	Butrans® (Purdue Pharma)	5; 7.5; 10; 15 and 20 mcg/h	Moderate to severe chronic pain
METHYLPHENIDATE TDS *	Bioequivalence Stage Product Developed	Daytrana® (Noven)	10; 15; 20 and 30 mg/9 hours	Attention Deficit Hyperactivity Disorder (ADHD)
DICLOFENAC SODIUM GEL 3%	Pharmaceutical Development Stage	Solaraze® (Fougera Pharmaceuticals)	3%	Actinic keratosis
DICLOFENAC EPOLAMINE TDS	Pharmaceutical Development Stage	Flector® (IBSA)	1.3%	Acute pain due to minor strains, sprains, and contusions
ESTRADIOL CREAM	Pharmaceutical Development Stage	Estrace® (Allergan)	0.01%	Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
LIDOCAINE TDS	Pharmaceutical Development Stage	Lidoderm® (Endo) Versatis® (Grünenthal)	5%	Pain relief associated with post-herpetic neuralgia
ROTIGOTINE TDS	Pharmaceutical Development Stage	Neupro® (UCB)	1; 2; 3; 4; 6 y 8 mg/24h	Parkinson disease
RASAGILINE TDS	Feasibility Tasks Stage	Azilect® (Teva) 505 (b)(2) / Hybrid	To be determined	Parkinson disease
GUANFACINE TDS	Feasibility Tasks Stage	Intuniv® (Shire) 505 (b)(2) / Hybrid	To be determined	Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
DONEPEZIL TDS	Feasibility Tasks Stage	Aricept (Eisai/Pfizer) 505 (b)(2) / Hybrid	To be determined	Treatment of dementia related to Alzheimer's disease

* Lower drug content and small patch size than the Reference Product.